Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2019

01-06-2019 | Anemia | Urologic Oncology

Development of a New Comorbidity Assessment Tool for Specific Prediction of Perioperative Mortality in Contemporary Patients Treated with Radical Cystectomy

Authors: Paolo Dell’Oglio, MD, Zhe Tian, MD, Sami-Ramzi Leyh-Bannurah, MD, Alessandro Larcher, MD, Elio Mazzone, MD, Marco Moschini, MD, Vincent Trudeau, MD, Armando Stabile, MD, Andrea Gallina, MD, Nazareno Suardi, MD, Umberto Capitanio, MD, Alexandre Mottrie, MD, Alberto Briganti, MD, Francesco Montorsi, MD, Christian M. Rochefort, PhD, Pierre I. Karakiewicz, MD

Published in: Annals of Surgical Oncology | Issue 6/2019

Login to get access

Abstract

Purpose

The Deyo adaptation of the Charlson comorbidity index (DaCCI), which relies on 17 comorbid condition groupings defined with 200 ICD-9-CM diagnostic codes, lacks specificity in the context of radical cystectomy (RC) for bladder cancer (BCa). We attempted to develop a new comorbidity assessment tool based on individual comorbid conditions and/or BCa manifestations for specific prediction of perioperative mortality after RC.

Methods

We relied on 7076 T1–T4 nonmetastatic BCa patients treated with RC between 2000 and 2009 in the SEER-Medicare linked database. Within the development cohort (n = 6076), simulated annealing (SA) was used to identify (1) individual comorbid conditions, (2) individual BCa manifestations, and (3) the combination of both, that satisfy the criteria of maximal accuracy and parsimony for prediction of 90-day mortality after RC, after adjusting for several confounders. The accuracy of the newly identified groups of individual comorbid conditions and/or BCa manifestations and of the original DaCCI was tested in a 1000-patient external validation cohort.

Results

The combination of six individual comorbid conditions and two individual BCa disease manifestations (type II diabetes without complications, anemia, chronic obstructive pulmonary disease, congestive heart failure, aortocoronary bypass, cardiomegaly, urinary tract infection, and hydronephrosis), and seven individual comorbid conditions (type II diabetes without complications, anemia, chronic obstructive pulmonary disease, congestive heart failure, aortocoronary bypass, osteoarthrosis, and cardiomegaly) respectively showed 71.1 and 70.2% accuracy versus 68.0% for the original DaCCI.

Conclusions

These new approaches are specific to contemporary RC patients and represent simpler methods compared with the original DaCCI, without any compromise in accuracy.
Appendix
Available only for authorised users
Literature
1.
Williams SB, Kamat AM, Chamie K, et al. Systematic review of comorbidity and competing-risks assessments for bladder cancer patients. Eur Urol Oncol. 2018;1(2):91–100.CrossRefPubMedPubMedCentral
2.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMed
3.
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.CrossRefPubMed
4.
Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27.CrossRefPubMed
5.
Saklad M. Grading of patients for surgical procedures. Anesthesiology 1941;2:281–4.CrossRef
6.
Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL, Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441–7.CrossRefPubMed
7.
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.CrossRefPubMed
8.
Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer. 1980;45(8):2220–4.CrossRefPubMed
9.
Dell’Oglio P, Tian Z, Leyh-Bannurah SR, et al. Short-form Charlson comorbidity index for assessment of perioperative mortality after radical cystectomy. J Natl Compr Cancer Netw. 2017;15(3):327–33.CrossRef
10.
Miller DC, Taub DA, Dunn RL, Montie JE, Wei JT. The impact of co-morbid disease on cancer control and survival following radical cystectomy. J Urol. 2003;169(1):105–9.CrossRefPubMed
11.
Witjes JA, Comperat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778–92.CrossRefPubMed
12.
Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 Suppl):IV-3-18.
13.
Kirkpatrick S, Gelatt CD, Jr., Vecchi MP. Optimization by simulated annealing. Science. 1983;220(4598):671–80.CrossRefPubMed
14.
Burnham KP, Anderson DR. Multimodel inference understanding AIC and BIC in model selection. Sociol Methods Res. 2004;33(2):261–304.CrossRef
15.
Burnham KP, Anderson DR. Model selection and multimodel inference: a practical information-theoretic approach. New York: Springer; 2002.
16.
Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–82.CrossRefPubMed
17.
Patel HD, Kates M, Pierorazio PM, et al. Comorbidities and causes of death in the management of localized T1a kidney cancer. Int J Urol. 2014;21(11):1086–92.CrossRefPubMed
18.
Higgins TL, Estafanous FG, Loop FD, Beck GJ, Blum JM, Paranandi L. Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients. A clinical severity score. JAMA. 1992;267(17):2344–8.PubMed
19.
Licker MJ, Widikker I, Robert J, et al. Operative mortality and respiratory complications after lung resection for cancer: impact of chronic obstructive pulmonary disease and time trends. Ann Thoracic Surg. 2006;81(5):1830–7.CrossRef
20.
Virani S, Michaelson JS, Hutter MM, et al. Morbidity and mortality after liver resection: results of the patient safety in surgery study. J Am Coll Surg. 2007;204(6):1284–92.CrossRefPubMed
21.
Davila JA, Rabeneck L, Berger DH, El-Serag HB. Postoperative 30-day mortality following surgical resection for colorectal cancer in veterans: changes in the right direction. Dig Dis Sci. 2005;50(9):1722–8.CrossRefPubMed
22.
Hammill BG, Curtis LH, Bennett-Guerrero E, et al. Impact of heart failure on patients undergoing major noncardiac surgery. Anesthesiology. 2008;108(4):559–67.CrossRefPubMed
23.
Wilt TJ, Cowper DC, Gammack JK, Going DR, Nugent S, Borowsky SJ. An evaluation of radical prostatectomy at Veterans Affairs Medical Centers: time trends and geographic variation in utilization and outcomes. Med Care. 1999;37(10):1046–56.CrossRefPubMed
24.
Musallam KM, Tamim HM, Richards T, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet. 2011;378(9800):1396–407.CrossRefPubMed
25.
Weiner MM, Reich DL, Lin HM, Krol M, Fischer GW. Influence of increased left ventricular myocardial mass on early and late mortality after cardiac surgery. Br J Anesth. 2013;110(1):41–6.CrossRef
26.
Noordzij PG, Boersma E, Schreiner F, et al. Increased preoperative glucose levels are associated with perioperative mortality in patients undergoing noncardiac, nonvascular surgery. Eur J Endocrinol. 2007;156(1):137–42.CrossRefPubMed
27.
Krolikowska M, Kataja M, Poyhia R, Drzewoski J, Hynynen M. Mortality in diabetic patients undergoing non-cardiac surgery: a 7-year follow-up study. Acta Anaesth Scand. 2009;53(6):749–58.CrossRefPubMed
28.
Thourani VH, Weintraub WS, Stein B, et al. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg. 1999;67(4):1045–52.CrossRefPubMed
29.
Haleblian GE, Skinner EC, Dickinson MG, Lieskovsky G, Boyd SD, Skinner DG. Hydronephrosis as a prognostic indicator in bladder cancer patients. J Urol. 1998;160(6 Pt 1):2011–4.CrossRefPubMed
30.
Bartsch GC, Kuefer R, Gschwend JE, de Petriconi R, Hautmann RE, Volkmer BG. Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series. Eur Urol. 2007;51(3):690–7; (discussion 697–698).CrossRefPubMed
31.
Mayr R, May M, Martini T, et al. Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder. BJU Int. 2012;110(6 Pt B):222–7.CrossRefPubMed
Metadata
Title
Development of a New Comorbidity Assessment Tool for Specific Prediction of Perioperative Mortality in Contemporary Patients Treated with Radical Cystectomy
Authors
Paolo Dell’Oglio, MD
Zhe Tian, MD
Sami-Ramzi Leyh-Bannurah, MD
Alessandro Larcher, MD
Elio Mazzone, MD
Marco Moschini, MD
Vincent Trudeau, MD
Armando Stabile, MD
Andrea Gallina, MD
Nazareno Suardi, MD
Umberto Capitanio, MD
Alexandre Mottrie, MD
Alberto Briganti, MD
Francesco Montorsi, MD
Christian M. Rochefort, PhD
Pierre I. Karakiewicz, MD
Publication date
01-06-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 6/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07313-y

Other articles of this Issue 6/2019

Annals of Surgical Oncology 6/2019 Go to the issue

Hepatobiliary Tumors

Living Donor Liver Transplant for Hepatocellular Carcinoma

Gastrointestinal Oncology

Diagnostic Accuracy and Usefulness of Intraoperative Margin Assessment by Frozen Section in Gastric Cancer

Hepatobiliary Tumors

Laparoscopic Left Lateral Sectionectomy Using the Extrahepatic Glissonean Approach: A Secure Option for Achieving a Negative Margin for Lesions with Ductal Extension

Colorectal Cancer

Response to Dr. Veld et al. Regarding the Manuscript Titled “What is the Best Option Between Primary Diverting Stoma or Endoscopic Stent as a Bridge to Surgery with a Curative Intent for Obstructed Left Colon Cancer? Results from a Propensity Score Analysis of the French Surgical Association Multicenter Cohort of 518 patients”

Translational Research and Biomarkers

Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients

Hepatobiliary Tumors

Fluorescent Tissue Assessment of Colorectal Cancer Liver Metastases Ablation Zone: A Potential Real-Time Biomarker of Complete Tumor Ablation